Trial Search Results

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated.

People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Boehringer Ingelheim

Stanford Investigator(s):


  • Drug: BI 836880


Phase 1/Phase 2


Inclusion Criteria:

   - Men and women over the age of 55 with active Choroidal Neovascularisation (CNV)
   secondary to Age-related macular degeneration (AMD) despite anti-Vascular Endothelial
   Growth Factor (VEGF) therapies (at least 3 prior injections with the last injection
   within 12 to 4 weeks before treatment). Active CNV secondary to AMD is to be defined
   either by recent fluorescein or Optical coherence tomography (OCT) angiogram within 4
   weeks prior to screening or fluorescein or OCT angiogram obtained prior to first anti
   VEGF-treatment to confirm the diagnosis and still active according to investigator

   - For MRD part only: Central subfield retinal thickness >350 microns in the study eye on
   Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT)

   - Presence of sub- and/or intraretinal fluid on SD-OCT in the study eye

   - Any active CNV with subfoveal leakage in the study eye as determined by OCT

   - No subretinal hemorrhage involving the fovea in the study eye No significant subfoveal
   fibrosis or atrophy on SD-OCT in the study eye that, in the opinion of the
   investigator, is able to prevent improvement in Best Corrected Visual Acuity (BCVA)
   and/or Central Subfield Thickness (CSFT)

   - Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA)
   in the study eye between 70 and 24 letters inclusive (approximately 20/40 and 20/320
   or 6/12 and 6/95) at screening.

   - Best-corrected VA in the non-study eye better than best-corrected VA in the study-eye.
   If both eyes are eligible and have identical VA the investigator may select the study

   - Male or female patients. Women of childbearing potential (WOCBP)1 cannot be included.
   Men able to father a child must be ready and able to use highly effective methods of
   birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per
   year when used consistently and correctly. A list of contraception methods meeting
   these criteria is provided in the patient information

   - Signed informed consent consistent with ICH GCP guidelines and local legislation prior
   to participation in the trial, which includes medication washout and restrictions

   - Not under any administrative or legal supervision or under institutionalization due to
   regulatory or juridical order

   - Further inclusion criteria apply

Exclusion criteria:

   - Additional eye disease in the study eye that could compromise best corrected Visual
   Acuity (VA)(BCVA) with visual field loss, uncontrolled glaucoma (Intra-Ocular Pressure
   (IOP)>24), clinically significant diabetic maculopathy, history of ischemic optic
   neuropathy or retinal vascular occlusion, symptomatic vitreomacular traction, or
   genetic disorders such as retinitis pigmentosa); history of high myopia > 8 diopters
   in the study eye. Anterior segment and vitreous abnormalities in the study eye that
   would preclude adequate observation with Spectral Domain Optical Coherence Tomography

   - Any prior intraocular surgery in the study eye other then uneventful lens replacement
   for cataract within 3 months prior to screening

   - Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser
   capsulotomy permitted, more than 3 month prior to enrollment in the study eye

   - Current or planned use of medications known to be toxic to the retina, lens or optic
   nerve (e.g. desferoxamine, chloroquine/hydrochloroquine, chlorpromazine,
   phenothiazines, tamoxifen, nicotinic acid, and ethambutol)

   - Medical history or condition: Uncontrolled diabetes mellitus, with hemoglobin A1c
   (HbA1c) > 10%, myocardial infarction or stroke within 12 months of screening, active
   bleeding disorder, concomitant use of warfarin or anticoagulation therapy (use of
   antiplatelet therapy such as aspirin is allowed), major surgery within 1 month of
   screening or when planned within the study period, hepatic impairment, uncontrolled

   - Patients with a clinically relevant abnormal screening haematology, blood chemistry,
   or urinalysis, if the abnormality defines a significant disease as defined in other
   exclusion criteria. AST or ALT greater than 2.0-fold the upper limit of normal at
   screening. Patients with total bilirubin 2.5x upper limit of normal at screening.

   - Patient with impaired renal function defined as calculated GFR< 30 mL/min

   - Significant alcohol or drug abuse within past 2 years per investigator judgement

   - Participation in trials:

      - Previous participation in this trial.

      - Previous participation in other trials for treatment of wAMD with systemic
      administration and/orif washout period from last administration is shorter than 3

      - MRD cohort 1: Previous participation in other trials for treatment of wAMD with
      IVT injections in the study eye if washout period from last
      administration/injection is shorter than 3 months.

      - MRD cohort 2: No previous IVT injections for wAMD in the study eye

   - Significant disease or other medical conditions (as determined by medical history,
   examination and clinical investigations at screening) that may, in the opinion of the
   investigator result in the any of the following:

      - Put the patient at risk because of participation in the study,

      - Influence the results of the study,

      - Cause concern regarding the patient's ability to participate in the study.

   - Known hypersensitivity to fluorescein or any of the ingredients used in the
   Investigational Medicinal Product (IMP) formulation, or any of the medications used

   - Active intraocular inflammation in the study eye

   - Active infectious conjunctivitis in either eye

Ages Eligible for Study

55 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Quan Nguyen
+001 (650) 724-4280